Publications by authors named "Y Korogi"
Background: We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer (SCLC).
Patients And Methods: Chemo-naïve patients with pathologically proven ED-SCLC (including limited disease (LD) SCLC with malignant effusion) were enrolled. Patients were randomized 1:1 to receive either AI (amrubicin 90mg/m on day 1 and irinotecan 50mg/m on days 1 and 8 of a 21-day cycle) or PI (cisplatin 60mg/m on day 1 and irinotecan 60mg/m on days 1, 8 and 15 of a 28-day cycle).
Article Synopsis
- PADRE imaging effectively enhances the visualization of myelin density, allowing for better differentiation of the superior cerebellar peduncle (SCP) in patients with progressive supranuclear palsy (PSP) compared to those with Parkinson's disease (PD).
- In a study involving 20 PSP and 31 PD patients, measurements revealed that the SCP was significantly smaller in PSP (1.1 mm) than in PD (2.4 mm), with PADRE achieving high diagnostic sensitivity (93.5%) and specificity (100%).
- The results demonstrated that PADRE imaging had superior diagnostic performance compared to traditional 3D-T1WI parameters for differentiating between PSP and PD.
Article Synopsis
- Visual hallucinations (VH) are common in Lewy body disease (LBD), including conditions like Parkinson's disease and dementia, and the study explored the use of phase difference enhanced imaging (PADRE) to identify structural changes in the optic radiation (OR) of these patients.
- Two radiologists analyzed the OR in healthy subjects and LBD patients to determine abnormalities, finding significant differences between those with VH and those without; they identified three distinct layers in healthy subjects' OR and defined abnormalities by obscured layers.
- The findings revealed that 57% of patients with LBD and identified abnormal OR developed VH during follow-up, suggesting that assessing OR abnormalities via PADRE could serve as a valuable marker to differentiate between patients with and
Article Synopsis
- A support vector machine (SVM) classifier was developed to analyze CT texture data for distinguishing between focal-type autoimmune pancreatitis (AIP) and pancreatic duct carcinoma (PD).
- The study involved 50 patients, where 62 CT texture features were extracted and analyzed using principal component analysis (PCA) to enhance the SVM classifier's accuracy.
- Results showed that the SVM significantly improved diagnostic performance for radiologists, increasing their accuracy in recognizing the two conditions, particularly benefiting those with less experience.